» Articles » PMID: 29595502

Pan-tuberculosis Regimens: an Argument Against

Overview
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2018 Mar 30
PMID 29595502
Citations 10
Authors
Affiliations
Soon will be listed here.
Citing Articles

Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.

James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R PLoS Med. 2024; 21(5):e1004401.

PMID: 38701084 PMC: 11101189. DOI: 10.1371/journal.pmed.1004401.


Multidrug-resistant tuberculosis.

Dheda K, Mirzayev F, Cirillo D, Udwadia Z, Dooley K, Chang K Nat Rev Dis Primers. 2024; 10(1):22.

PMID: 38523140 DOI: 10.1038/s41572-024-00504-2.


Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?.

Prasad R, Singh A, Gupta N Indian J Tuberc. 2022; 69(4):377-382.

PMID: 36460365 PMC: 9221684. DOI: 10.1016/j.ijtb.2022.06.006.


A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB.

Memani B, Furin J, Cox H, Reuter A Int J Tuberc Lung Dis. 2022; 26(12):1180-1182.

PMID: 36447309 PMC: 9728944. DOI: 10.5588/ijtld.22.0335.


MDR Tuberculosis Treatment.

Espinosa-Pereiro J, Sanchez-Montalva A, Aznar M, Espiau M Medicina (Kaunas). 2022; 58(2).

PMID: 35208510 PMC: 8878254. DOI: 10.3390/medicina58020188.